Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.

Oppenheimer Holdings, Inc. reaffirmed their outperform rating on shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in a report published on Thursday. The firm currently has a $83.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $75.00. Oppenheimer Holdings also issued estimates for Agios Pharmaceuticals’ Q3 2017 earnings at ($1.99) EPS, Q4 2017 earnings at ($2.04) EPS, Q1 2018 earnings at ($2.31) EPS, Q2 2018 earnings at ($2.31) EPS, Q3 2018 earnings at ($2.45) EPS, Q4 2018 earnings at ($0.21) EPS, FY2018 earnings at ($7.28) EPS, FY2019 earnings at ($1.43) EPS and FY2020 earnings at $3.10 EPS.

Other research analysts have also recently issued reports about the stock. SunTrust Banks, Inc. reissued a buy rating and issued a $80.00 price objective (up from $68.00) on shares of Agios Pharmaceuticals in a research note on Tuesday, August 8th. Needham & Company LLC boosted their target price on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a buy rating in a research note on Thursday. Cann reaffirmed a buy rating and set a $75.00 target price on shares of Agios Pharmaceuticals in a research note on Sunday, June 11th. Leerink Swann raised shares of Agios Pharmaceuticals from a market perform rating to an outperform rating and boosted their target price for the stock from $50.00 to $80.00 in a research note on Wednesday, August 2nd. Finally, Janney Montgomery Scott reaffirmed a hold rating on shares of Agios Pharmaceuticals in a research note on Tuesday, August 1st. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Agios Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $74.75.

Shares of Agios Pharmaceuticals (NASDAQ:AGIO) opened at 58.86 on Thursday. The company’s 50-day moving average price is $56.90 and its 200-day moving average price is $51.87. The company’s market capitalization is $2.85 billion. Agios Pharmaceuticals has a 52-week low of $35.84 and a 52-week high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.57) by $0.21. The firm had revenue of $11.30 million during the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative net margin of 502.12% and a negative return on equity of 68.15%. The business’s revenue was up 62.1% compared to the same quarter last year. During the same period last year, the business earned ($1.47) earnings per share. Equities research analysts forecast that Agios Pharmaceuticals will post ($6.90) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc.” was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://weekherald.com/2017/08/13/agios-pharmaceuticals-inc-nasdaqagio-stock-rating-reaffirmed-by-oppenheimer-holdings-inc.html.

In related news, insider Scott Biller sold 23,146 shares of the business’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $59.60, for a total value of $1,379,501.60. Following the sale, the insider now owns 8,410 shares of the company’s stock, valued at $501,236. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO David P. Schenkein sold 27,000 shares of the business’s stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $59.95, for a total transaction of $1,618,650.00. Following the completion of the sale, the chief executive officer now directly owns 3,000 shares in the company, valued at approximately $179,850. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 79,120 shares of company stock worth $4,557,207. Insiders own 10.55% of the company’s stock.

Several hedge funds have recently modified their holdings of AGIO. FMR LLC boosted its stake in shares of Agios Pharmaceuticals by 14.1% in the second quarter. FMR LLC now owns 7,227,331 shares of the biopharmaceutical company’s stock valued at $371,846,000 after buying an additional 895,584 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Agios Pharmaceuticals by 23.8% in the second quarter. Vanguard Group Inc. now owns 3,214,770 shares of the biopharmaceutical company’s stock valued at $165,401,000 after buying an additional 617,379 shares in the last quarter. BB Biotech AG boosted its stake in shares of Agios Pharmaceuticals by 1.1% in the second quarter. BB Biotech AG now owns 2,869,528 shares of the biopharmaceutical company’s stock valued at $147,637,000 after buying an additional 30,000 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Agios Pharmaceuticals by 23.5% in the second quarter. BlackRock Inc. now owns 2,675,380 shares of the biopharmaceutical company’s stock valued at $137,648,000 after buying an additional 508,306 shares in the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of Agios Pharmaceuticals by 52.3% in the second quarter. First Trust Advisors LP now owns 973,870 shares of the biopharmaceutical company’s stock valued at $50,106,000 after buying an additional 334,291 shares in the last quarter. 84.53% of the stock is currently owned by institutional investors.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply